Arrowhead Research ARWR Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arrowhead Research's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arrowhead Research's retained earnings?
- Arrowhead Research (ARWR) reported retained earnings of -$1.73B in Q1 2026.
- How has Arrowhead Research's retained earnings changed year-over-year?
- Arrowhead Research's retained earnings decreased by 21.1% year-over-year, from -$1.43B to -$1.73B.
- What is the long-term trend for Arrowhead Research's retained earnings?
- Over 5 years (2020 to 2025), Arrowhead Research's retained earnings has grown at a 26.4% compound annual growth rate (CAGR), from -$503.84M to -$1.63B.
- What does retained earnings mean?
- The total profit the company has kept and reinvested since it started, rather than paying out as dividends.
- How do you interpret retained earnings?
- A growing positive balance indicates profitability, while a deepening negative balance reflects ongoing investment in drug development exceeding current revenues.
- How does retained earnings compare across companies?
- Most pre-commercial biotech companies maintain negative retained earnings due to the high cost of clinical development.